Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation.
Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation.
复制标题
DOI：
10.1016/j.immuni.2016.05.001
复制
发表时间：
2016-05-17
期刊：
影响因子：
32.4
通讯作者：
Kuchroo VK
中科院分区：
文献类型：
--
作者：
Anderson AC;Joller N;Kuchroo VK
共抑制受体，如CTLA-4和PD-1，在调节T细胞反应中具有重要作用，并已被证明是慢性疾病的有效靶点，在T细胞上结构性共抑制受体的表达抑制效应性T细胞反应。不幸的是，许多患者仍然对针对CTLA-4和PD-1的治疗没有反应。下一波正在临床试验中探索的共抑制受体靶点包括LAG-3、TIM-3和TIGIT。这些受体虽然与PD-1和CTLA-4属于同一类受体，但具有独特的功能，特别是在它们调节免疫不同方面的组织部位。增加对这些受体的特殊功能的了解将为临床合理应用针对这些受体的治疗提供信息。
Co-inhibitory receptors, such as CTLA-4 and PD-1, have an important role in regulating T cell responses and have proven to be effective targets in the setting of chronic diseases where constitutive co-inhibitory receptor expression on T cells dampens effector T cell responses. Unfortunately, many patients still fail to respond to therapies that target CTLA-4 and PD-1. The next wave of co-inhibitory receptor targets that are being explored in clinical trials include Lag-3, Tim-3, and TIGIT. These receptors while belonging to the same class of receptors as PD-1 and CTLA-4 exhibit unique functions especially at tissue sites where they regulate distinct aspects of immunity. Increased understanding of the specialized functions of these receptors will inform the rational application of therapies that target these receptors to the clinic.